Interim Analysis of Real-world patient experience of Vildagliptin 100mg SR OD in terms of Glycaemic Variability out now

A recent prospective, multicentric, observational study conducted in patients with diabetes assessed the real-world experience of Vildagliptin 100mg SR OD in terms of glycaemic variability.

A total of 48 study individuals were included in the study with a mean age of 55.0 years and the mean duration of T2DM was 8.8 ± 7.7 years.

At the end of the study period, it was observed that there is a decreasing trend in the mean glucose levels and an increasing trend in the mean Time in range (%) when compared with the baseline values. There is also an increasing trend in the proportion of patients spending with average sugar levels between 70-120 mg/dl for at least 70% of time during the day from baseline (46%) to week one (42%) and two (52%).

This study provides real-world data on the effectiveness and safety profile of vildagliptin in patients with uncontrolled T2DM. These results obtained in a real-world setting clearly validate the results from previous randomized clinical trials (RCTs) conducted with vildagliptin and confirms the effectiveness of vildagliptin in daily clinical practice.

In this video, Dr Abhijit Bhograj talks about the Real-world patient experience of Vildagliptin 100mg SR OD in terms of Glycaemic Variability.